A spinoff from the Ben-Yakar Lab in the Mechanical Engineering Department at the University of Texas at Austin, Newormics is structured around development of the first high-throughput, high-content screening platforms for use with in vivo small animal models as well as in vitro 3D tissue organoids. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions.
